230 related articles for article (PubMed ID: 3356465)
21. Francisella tularensis selectively induces proinflammatory changes in endothelial cells.
Forestal CA; Benach JL; Carbonara C; Italo JK; Lisinski TJ; Furie MB
J Immunol; 2003 Sep; 171(5):2563-70. PubMed ID: 12928407
[TBL] [Abstract][Full Text] [Related]
22. Francisella tularensis resistance to bactericidal action of normal human serum.
Sorokin VM; Pavlovich NV; Prozorova LA
FEMS Immunol Med Microbiol; 1996 Mar; 13(3):249-52. PubMed ID: 8861038
[TBL] [Abstract][Full Text] [Related]
23. A defined O-antigen polysaccharide mutant of Francisella tularensis live vaccine strain has attenuated virulence while retaining its protective capacity.
Sebastian S; Dillon ST; Lynch JG; Blalock LT; Balon E; Lee KT; Comstock LE; Conlan JW; Rubin EJ; Tzianabos AO; Kasper DL
Infect Immun; 2007 May; 75(5):2591-602. PubMed ID: 17296751
[TBL] [Abstract][Full Text] [Related]
24. A panel of correlates predicts vaccine-induced protection of rats against respiratory challenge with virulent Francisella tularensis.
De Pascalis R; Hahn A; Brook HM; Ryden P; Donart N; Mittereder L; Frey B; Wu TH; Elkins KL
PLoS One; 2018; 13(5):e0198140. PubMed ID: 29799870
[TBL] [Abstract][Full Text] [Related]
25. Francisella tularensis vaccines.
Griffin KF; Oyston PC; Titball RW
FEMS Immunol Med Microbiol; 2007 Apr; 49(3):315-23. PubMed ID: 17316369
[TBL] [Abstract][Full Text] [Related]
26. A mutant of Francisella tularensis strain SCHU S4 lacking the ability to express a 58-kilodalton protein is attenuated for virulence and is an effective live vaccine.
Twine S; Byström M; Chen W; Forsman M; Golovliov I; Johansson A; Kelly J; Lindgren H; Svensson K; Zingmark C; Conlan W; Sjöstedt A
Infect Immun; 2005 Dec; 73(12):8345-52. PubMed ID: 16299332
[TBL] [Abstract][Full Text] [Related]
27. Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.
Richard K; Mann BJ; Qin A; Barry EM; Ernst RK; Vogel SN
Clin Vaccine Immunol; 2017 Mar; 24(3):. PubMed ID: 28077440
[No Abstract] [Full Text] [Related]
28. Uptake of serum-opsonized Francisella tularensis by macrophages can be mediated by class A scavenger receptors.
Pierini LM
Cell Microbiol; 2006 Aug; 8(8):1361-70. PubMed ID: 16882038
[TBL] [Abstract][Full Text] [Related]
29. Specific antibodies protect gamma-irradiated mice against Francisella tularensis infection.
Kubelkova K; Krocova Z; Balonova L; Pejchal J; Stulik J; Macela A
Microb Pathog; 2012; 53(5-6):259-68. PubMed ID: 22841607
[TBL] [Abstract][Full Text] [Related]
30. Phagocytosis of Francisella tularensis by Rhesus monkey peripheral leukocytes.
Proctor RA; White JD; Ayala E; Canonico PG
Infect Immun; 1975 Jan; 11(1):146-51. PubMed ID: 234911
[TBL] [Abstract][Full Text] [Related]
31. Increased encapsulation and virulence of Francisella tularensis live vaccine strain (LVS) by subculturing on synthetic medium.
Cherwonogrodzky JW; Knodel MH; Spence MR
Vaccine; 1994 Jul; 12(9):773-5. PubMed ID: 7975855
[TBL] [Abstract][Full Text] [Related]
32. Elucidation of a mechanism of oxidative stress regulation in Francisella tularensis live vaccine strain.
Ma Z; Russo VC; Rabadi SM; Jen Y; Catlett SV; Bakshi CS; Malik M
Mol Microbiol; 2016 Sep; 101(5):856-78. PubMed ID: 27205902
[TBL] [Abstract][Full Text] [Related]
33. Francisella tularensis inhibits the intrinsic and extrinsic pathways to delay constitutive apoptosis and prolong human neutrophil lifespan.
Schwartz JT; Barker JH; Kaufman J; Fayram DC; McCracken JM; Allen LA
J Immunol; 2012 Apr; 188(7):3351-63. PubMed ID: 22357630
[TBL] [Abstract][Full Text] [Related]
34. Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion.
Baron SD; Singh R; Metzger DW
Infect Immun; 2007 May; 75(5):2152-62. PubMed ID: 17296747
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of Francisella tularensis ΔpdpC as a candidate live attenuated vaccine against respiratory challenge by a virulent SCHU P9 strain of Francisella tularensis in a C57BL/6J mouse model.
Tian D; Uda A; Park ES; Hotta A; Fujita O; Yamada A; Hirayama K; Hotta K; Koyama Y; Azaki M; Morikawa S
Microbiol Immunol; 2018 Jan; 62(1):24-33. PubMed ID: 29171073
[TBL] [Abstract][Full Text] [Related]
36. Potential source of Francisella tularensis live vaccine strain attenuation determined by genome comparison.
Rohmer L; Brittnacher M; Svensson K; Buckley D; Haugen E; Zhou Y; Chang J; Levy R; Hayden H; Forsman M; Olson M; Johansson A; Kaul R; Miller SI
Infect Immun; 2006 Dec; 74(12):6895-906. PubMed ID: 17000723
[TBL] [Abstract][Full Text] [Related]
37. Intranasal administration of a two-dose adjuvanted multi-antigen TMV-subunit conjugate vaccine fully protects mice against Francisella tularensis LVS challenge.
McCormick AA; Shakeel A; Yi C; Kaur H; Mansour AM; Bakshi CS
PLoS One; 2018; 13(4):e0194614. PubMed ID: 29684046
[TBL] [Abstract][Full Text] [Related]
38. Influence of the Escherichia coli capsule on complement fixation and on phagocytosis and killing by human phagocytes.
Horwitz MA; Silverstein SC
J Clin Invest; 1980 Jan; 65(1):82-94. PubMed ID: 6985617
[TBL] [Abstract][Full Text] [Related]
39. Genetic engineering of Francisella tularensis LVS for use as a novel live vaccine platform against Pseudomonas aeruginosa infections.
Robinson CM; Kobe BN; Schmitt DM; Phair B; Gilson T; Jung JY; Roberts L; Liao J; Camerlengo C; Chang B; Davis M; Figurski L; Sindeldecker D; Horzempa J
Bioengineered; 2015; 6(2):82-8. PubMed ID: 25617059
[TBL] [Abstract][Full Text] [Related]
40. Francisella tularensis LVS initially activates but subsequently down-regulates intracellular signaling and cytokine secretion in mouse monocytic and human peripheral blood mononuclear cells.
Telepnev M; Golovliov I; Sjöstedt A
Microb Pathog; 2005; 38(5-6):239-47. PubMed ID: 15925273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
